Merck Ventures director Andreas Jurgeit has departed after two years to become a partner at another corporate investor, Lundbeckfonden Emerge.
Andreas Jurgeit, formerly a director at Germany-based pharmaceutical firm Merck Group’s corporate venturing arm, Merck Ventures, is to join life sciences foundation Lundbeck Foundation’s early-stage investment unit, Lundbeckfonden Emerge.
Denmark-based Lundbeckfonden Emerge, which has hired Jurgeit as a partner, invests in biotech, life sciences, pharmaceutical and healthcare technology developers. Its portfolio companies include mucosal disease therapy developer Afyx Therapeutics and neuromuscular disorder-focused NMD Pharma.
Jurgeit has experience in R&D in target discovery and drug development from his doctoral and post-doctoral…
